v3.25.2
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 11, 2024
Mar. 31, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Jun. 06, 2023
Offsetting Assets [Line Items]                
Fair value of warrants             $ 2,015,413  
Amortization of debt issuance costs         $ 769,441    
Unamortized debt issuance costs     $ 1,534,413   1,534,413   1,870,316  
Interest expense     48,750 $ 1,171,963 357,672 $ 2,559,456    
Line of Credit [Member]                
Offsetting Assets [Line Items]                
Amortization of debt issuance costs     $ 167,951   $ 335,903      
Warrant [Member]                
Offsetting Assets [Line Items]                
Fair value of common stock     $ 12.00   $ 12.00      
Expected volatility         86.00%      
Risk-free interest rate         4.82%      
Term         2 years 6 months      
Orient EuroPharma Co., Ltd. [Member]                
Offsetting Assets [Line Items]                
Litigation settlement payable     $ 4,000,000   $ 4,000,000   4,000,000,000  
Vendor [Member]                
Offsetting Assets [Line Items]                
Litigation settlement payable               $ 600,000
Interest expense     48,750   56,250      
Accrued interest     $ 97,500   $ 97,500   $ 41,250  
Line of Credit Agreement [Member] | HCWG [Member]                
Offsetting Assets [Line Items]                
Line of credit $ 10,000,000.0              
Line of credit, interest rate 10.00%              
Number of warrants to purchase 312,500              
Exercise price $ 12.00              
Warrants expiration date Oct. 23, 2029              
Warrants issued             312,500  
Warrants outstanding             312,500  
Warrants vested             312,500  
Warrants exercised   162,500            
Issuance of common stock   162,500            
Line of Credit Agreement [Member] | HCWG [Member] | Warrant [Member]                
Offsetting Assets [Line Items]                
Common stock remaining available of issuance     150,000   150,000